Literature DB >> 25542996

GABAA α5 subunit-containing receptors do not contribute to reversal of inflammatory-induced spinal sensitization as indicated by the unique selectivity profile of the GABAA receptor allosteric modulator NS16085.

A Garcia de Lucas1, P K Ahring2, J S Larsen3, I Rivera-Arconada1, J A Lopez-Garcia1, N R Mirza3, G Munro4.   

Abstract

GABAA receptor positive allosteric modulators (PAMs) mediate robust analgesia in animal models of pathological pain. Restoration of diminished spinal GABAA-α2 and -α3 subunit-containing receptor function is a principal contributor to this analgesia, albeit involvement of GABAA-α5-receptors has not been excluded. Thus, we compared NS11394 and TPA023 (PAMs with selectivity/efficacy at GABAA-α2/α3/α5 receptors) with TP003 (a reportedly GABAA-α3 selective PAM) against spinal sensitization. However, in-house electrophysiology studies designed to confirm the selectivity of TPA023 and TP003 for human GABAA receptors did not corroborate published data, with TP003 displaying considerable GABAA-α5 receptor efficacy. Therefore, we identified a novel PAM, NS16085, which possesses negligible efficacy at GABAA-α5 receptors, but with GABAA-α2/α3 efficacy equivalent to NS11394. At the GABAA-α1 receptor the compound gives low level of negative modulation further separating it from the other compounds. Rat pups with carrageenan-induced hindpaw inflammatory hyperalgesia were used to make ex vivo spinal dorsal root-evoked ventral root recordings. Some spontaneous activity and large numbers of spikes to repetitive stimulation of dorsal roots at C-fibre intensity, indicative of wind-up and sensitization were observed. Equimolar concentrations of NS11394, TP003 and NS16085 all attenuated wind-up to a similar degree; TPA023 was clearly less effective. In adult rats, NS16085 (3-30 mg/kg, p.o.) dose-dependently reduced formalin-induced hindpaw flinching with efficacy comparable to NS11394. Thus, potentiation of GABAA-α2 and-α3 receptors is sufficient to depress spinal sensitization and mediate analgesia after inflammatory injury. Positive modulation at GABAA-α5-receptors is apparently dispensable for this process, an important consideration given the role of this receptor subtype in cognitive function.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Analgesia; Central sensitization; Hyperalgesia; Pain; Spinal inhibition; Wind-up

Mesh:

Substances:

Year:  2014        PMID: 25542996     DOI: 10.1016/j.bcp.2014.12.010

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  13 in total

Review 1.  Human pharmacology of positive GABA-A subtype-selective receptor modulators for the treatment of anxiety.

Authors:  Xia Chen; Joop van Gerven; Adam Cohen; Gabriel Jacobs
Journal:  Acta Pharmacol Sin       Date:  2018-12-05       Impact factor: 6.150

2.  Pharmacological and antihyperalgesic properties of the novel α2/3 preferring GABAA receptor ligand MP-III-024.

Authors:  Bradford D Fischer; Raymond J Schlitt; Bryan Z Hamade; Sabah Rehman; Margot Ernst; Michael M Poe; Guanguan Li; Revathi Kodali; Leggy A Arnold; James M Cook
Journal:  Brain Res Bull       Date:  2017-03-04       Impact factor: 4.077

3.  Antinociceptive Effects of a Novel α2/α3-Subtype Selective GABAA Receptor Positive Allosteric Modulator.

Authors:  Lakeisha A Lewter; Janet L Fisher; Justin N Siemian; Kashi Reddy Methuku; Michael M Poe; James M Cook; Jun-Xu Li
Journal:  ACS Chem Neurosci       Date:  2017-02-13       Impact factor: 4.418

4.  Anti-Tremor Action of Subtype Selective Positive Allosteric Modulators of GABAA Receptors in a Rat Model of Essential Tremors.

Authors:  Dipak V Amrutkar; Tino Dyhring; Thomas A Jacobsen; Janus S Larsen; Karin Sandager-Nielsen
Journal:  Cerebellum       Date:  2020-04       Impact factor: 3.847

5.  Allosteric Modulation of GABAA Receptors in Rat Basolateral Amygdala Blocks Stress-Enhanced Reacquisition of Nicotine Self-Administration.

Authors:  Burt M Sharp; Qin Jiang; Xenia Simeone; Petra Scholze
Journal:  ACS Pharmacol Transl Sci       Date:  2020-10-19

6.  A Multifaceted GABAA Receptor Modulator: Functional Properties and Mechanism of Action of the Sedative-Hypnotic and Recreational Drug Methaqualone (Quaalude).

Authors:  Harriet Hammer; Benjamin M Bader; Corina Ehnert; Christoffer Bundgaard; Lennart Bunch; Kirsten Hoestgaard-Jensen; Olaf H-U Schroeder; Jesper F Bastlund; Alexandra Gramowski-Voß; Anders A Jensen
Journal:  Mol Pharmacol       Date:  2015-06-08       Impact factor: 4.436

Review 7.  An Emerging Circuit Pharmacology of GABAA Receptors.

Authors:  Elif Engin; Rebecca S Benham; Uwe Rudolph
Journal:  Trends Pharmacol Sci       Date:  2018-06-11       Impact factor: 14.819

8.  A Pharmacogenetic 'Restriction-of-Function' Approach Reveals Evidence for Anxiolytic-Like Actions Mediated by α5-Containing GABAA Receptors in Mice.

Authors:  Lauren M Behlke; Rachel A Foster; Jing Liu; Dietmar Benke; Rebecca S Benham; Anna J Nathanson; Benjamin K Yee; Hanns Ulrich Zeilhofer; Elif Engin; Uwe Rudolph
Journal:  Neuropsychopharmacology       Date:  2016-04-12       Impact factor: 7.853

9.  Evaluation of the anti-conflict, reinforcing, and sedative effects of YT-III-31, a ligand functionally selective for α3 subunit-containing GABAA receptors.

Authors:  Zhiqiang Meng; Lais F Berro; Eileen K Sawyer; Daniela Rüedi-Bettschen; Jemma E Cook; Guanguan Li; Donna M Platt; James M Cook; James K Rowlett
Journal:  J Psychopharmacol       Date:  2019-10-31       Impact factor: 4.153

10.  Synergistic antihyperalgesic and antinociceptive effects of morphine and methyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate (MP-III-024): a positive allosteric modulator at α2GABAA and α3GABAA receptors.

Authors:  Mohammad A Rahman; Thomas M Keck; Michael M Poe; Dishary Sharmin; James M Cook; Bradford D Fischer
Journal:  Psychopharmacology (Berl)       Date:  2021-02-13       Impact factor: 4.415

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.